BRAF inhibitors: the current and the future
Author:
Publisher
Elsevier BV
Subject
Drug Discovery,Pharmacology
Reference43 articles.
1. Mutations of the BRAF gene in human cancer;Davies;Nature,2002
2. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis;Wilhelm;Cancer Res,2004
3. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma;Hauschild;J Clin Oncol,2009
4. Inhibition of mutated, activated BRAF in metastatic melanoma;Flaherty;N Engl J Med,2010
5. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib;Sosman;N Engl J Med,2012
Cited by 37 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Rapid but nondurable response of a BRAF exon 15 double-mutated spindle cell sarcoma to a combination of BRAF and MEK inhibitors;Oncotarget;2024-07-17
2. Naphthoquinone Derivatives Targeting Melanoma;Current Topics in Medicinal Chemistry;2023-12
3. BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of Resistance: A Review of the Literature;Cancers;2023-10-31
4. An updated literature on BRAF inhibitors (2018–2023);Molecular Diversity;2023-07-20
5. Computational analysis of natural product B-Raf inhibitors;Journal of Molecular Graphics and Modelling;2023-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3